Tissue-based molecular markers for bladder cancer

Minerva Urologica e Nefrologica

Volumn 62, Issue 3, 2010, Pages 241-258

  Barbieri, C E ^a   Lotan, Y ^b   Lee, R K ^a   Sonpavde, G ^c   Karakiewicz, P I ^d   Robinson, B ^e   Scherr, D S ^a   Shariat, S F ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Molecular biology; Prognosis; Urinary bladder neoplasms

Indexed keywords

ANDROGEN RECEPTOR; BASIC FIBROBLAST GROWTH FACTOR; CASPASE 3; CISPLATIN; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN E; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FAS ANTIGEN; FIBROBLAST GROWTH FACTOR RECEPTOR 3; KI 67 ANTIGEN; METHOTREXATE; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P27; PROTEIN P53; RAS PROTEIN; RETINOBLASTOMA PROTEIN; SURVIVIN; THROMBOSPONDIN 1; VASCULOTROPIN; VINBLASTINE;

ADJUVANT THERAPY; ANGIOGENESIS; ANTIGEN EXPRESSION; APOPTOSIS; BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL CYCLE S PHASE; CYSTECTOMY; DNA DAMAGE; DNA POLYMORPHISM; DNA REPAIR; DRUG EFFICACY; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; HUMAN; IMMUNOHISTOCHEMISTRY; PREDICTIVE VALIDITY; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION; TRANSITIONAL CELL CARCINOMA; TUMOR DIFFERENTIATION; TUMOR SUPPRESSOR GENE;

CYCLIN-DEPENDENT KINASE INHIBITOR P21; HUMANS; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 78751686486     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (134)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin
2. Shariat SF, Casella R, Wians FH Jr, Ashfaq R, Balko J, Sulser T et al. Risk stratification for bladder tumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology. Eur Urol 2004;45(3):304-13; author reply 313
3. Shariat SF, Casella R, Khoddami SM, Hernandez G, Sulser T, Gasser TC et al. Urine detection of survivin is a sensitive marker for the noninvasive diagnosis of bladder cancer. J Urol 2004;171(2 Pt 1):626-30.
4. Lotan Y, Shariat SF. Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection. BJU Int 2008;101:1362-7.
5. Bochner BH. Optimal timing of radical cystectomy for patients with T1 bladder cancer. Urol Oncol 2009;27:329-31.
6. Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 2006;176(6 Pt 1):2414-22; discussion 2422
7. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1 054 patients. J Clin Oncol 2001;19:666-75.
8. Herman MP, Svatek RS, Lotan Y, Karakiewizc PI, Shariat SF. Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer. Minerva Urol Nefrol 2008;60:217-35.
9. Bensalah K, Montorsi F, Shariat SF. Challenges of cancer biomarker profiling. Eur Urol 2007;52:1601-9. (Pubitemid 350052431)
10. Lotan Y. Role of biomarkers to predict outcomes and response to therapy. Urologic Oncology: Seminars and Original Investigations 2010;28:97-101.
11. Shariat SF, Canto EI, Kattan MW, Slawin KM. Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer. Rev Urol 2004;6:58-72
12. Shariat SF, Karam JA, Roehrborn CG. Blood biomarkers for prostate cancer detection and prognosis. Future Oncol 2007;3:449-61.
13. Shariat SF, Kattan MW, Vickers AJ, Karakiewicz PI, Scardino PT. Critical review of prostate cancer predictive tools. Future Oncol 2009;5:1555-84.
14. Shariat SF, Lotan Y, Vickers A, Karakiewicz PI, Schmitz-Dräger BJ, Goebell PJ et al. Statistical consideration for clinical biomarker research in bladder cancer. Urol Oncol 2010;28:389-400.
15. Malats N, Bustos A, Nascimento CM, Fernandez F, Rivas M, Puente D et al. P53 as a prognostic marker for bladder cancer: a meta-analysis and review. Lancet Oncol 2005,6:678-86.
16. Dalbagni G, Parekh DJ, Ben-Porat L, Potenzoni M, Herr HW, Reuter VE. Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder. BJU Int 2007;99:281-5. (Pubitemid 46103104)
17. Svatek RS, Jeldres C, Karakiewicz PI, Suardi N, Walz J, Roehrborn CG et al. Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence. Prostate 2009;69:886-94.
18. Bensalah K, Lotan Y, Karam JA, Shariat SF. New circulating biomarkers for prostate cancer. Prostate Cancer Prostatic Dis 2008;11:112-20.
19. Check E. Proteomics and cancer: running before we can walk? Nature 2004;429:496-7.
20. Diamandis EP. Proteomic patterns to identify ovarian cancer: 3 years on. Expert Rev Mol Diagn 2004;4:575-7.
21. Verma M, Srivastava S. New cancer biomarkers deriving from NCI early detection research. Recent Results Cancer Res 2003;163:72-84; discussion 264-266
22. Winget MD, Baron JA, Spitz MR, Brenner DE, Warzel D, Kincaid H et al. Development of common data elements: the experience of and recommendations from the early detection research network. Int J Med Inform 2003;70:41-8.
23. Goebell PJ, Groshen SL, Schmitz-Drager BJ. Guidelines for development of diagnostic markers in bladder cancer. World J Urol 2008;26:5-11.
24. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Urol 2005;2:416-22.
25. Mallett S, Timmer A, Sauerbrei W, Altman DG. Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines. Br J Cancer 2010;102:173-80.
26. Hayes DF, Bast RC, Desch CE, Fritsche H Jr, Kemeny NE, Jessup JM et al. Tumor marker utility grading systern: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88:1456-66.
27. Shariat SF, Karakiewicz PI. Perspectives on prostate cancer biomarkers. Eur Urol 2008;54:8-10.
28. Shariat SF, Karakiewicz PI, Roehrborn CG, Kattan MW. An updated catalog of prostate cancer predictive tools. Cancer 2008;113:3075-99.
29. Shariat SF, Karam JA, Margulis V, Karakiewicz PI. New blood-based biomarkers for the diagnosis, staging and prognosis of prostate cancer. BJU Int 2008;101:675-83.
30. Shariat SF, Karam JA, Walz J, Roehrborn CG, Montorsi F, Margulis V et al. Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin Cancer Res 2008;14:3785-91.
31. Margulis V, Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res 2006;12:7369-73. (Pubitemid 46095410)
32. Margulis V, Lotan Y, Karakiewicz PI, Fradet Y, Ashfaq R, Capitanio U et al. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst 2009;101:114-9.
33. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
34. Ruas M, Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1998;1378:F115-77.
35. Esrig D, Spruck CH 3rd, Nichols PW, Chaiwun B, Steven K, Groshen S et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol 1993;143:1389-97.
36. Cote RJ, Dunn MD, Chatterjee SJ, Stein JP, Shi SR, Tran QC et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 1998;58:1090-4.
37. Grossman HB, Liebert M, Antelo M, Dinney CP, Hu SX, Palmer JL et al. p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res 1998;4:829-34.
38. Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang ZF, Sheinfeld J, Fair WR et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Nad Cancer Inst 1993;85:53-9.
39. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994;331:1259-64.
40. Stein JP, Ginsberg DA, Grossfeld GD, Chatterjee SJ, Esrig D, Dickinson MG et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 1998;90:1072-9.
41. Tokunaga H, Shariat SF, Green AE, Brown RM, Zhou JH, Benedict WF et al. Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens. Int J Radiat Oncol Biol Phys 2001;51:16-22.
42. Benedict WF, Lerner SP, Zhou J, Shen X, Tokunaga H, Czerniak B. Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer. Oncogene 1999;18:1197-203. (Pubitemid 29085992)
43. Cordon-Cardo C, Wartinger D, Petrylak D, Dalbagni G, Fair WR, Fuks Z et al. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst 1992;84:1251-6.
44. Shariat SF, Tokunaga H, Zhou J, Kim J, Ayala GE, Benedict WF etat. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 2004;22:1014-24
45. Chatterjee SJ, Datar R, Youssefzadeh D, George B, Goebell PJ, Stein JP et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 2004;22:1007-13.
46. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder. Urol Oncol 2007;25:468-75.
47. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J Urol 2007;177:481-7; discussion 487.
48. Bensalah K, Traxer O, Shariat SF, Zimmern P. [What are the differences between American and French urologists?]. Prog Urol 2007;17:1367-71.
49. Shariat SF, Karakiewicz PI, Ashfaq R, Lerner SP, Palapattu GS, Cote RJ et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 2008;112:315-25.
50. Shariat SF, Kim J, Raptidis G, Ayala GE, Lerner SP. Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology 2003;61:1140-5. (Pubitemid 36693989)
51. Shariat SF, Lotan Y, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y et al. p53 predictive value for pT1-2 NO disease at radical cystectomy. J Urol 2009;182:907-13.
52. Shariat SF, Weizer AZ, Green A, Laucirica R, Frolov A, Wheeler TM et al. Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. Urology 2000;56:735-40.
53. Shariat SF, Zlotta AR, Ashfaq R, Sagalowsky AI, Lotan Y. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol 2007;20:445-59.
54. Dalbagni G, Presti J, Reuter V, Fair WR, Cordon-Cardo C. Genetic alterations in bladder cancer. Lancet 1993;342:469-71.
55. Knowles MA, Elder PA, Williamson M, Cairns JP, Shaw ME, Law MG. Allelotype of human bladder cancer. Cancer Res 1994;54:531-8.
56. Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. Hum Pathol 2006;37:1568-76.
57. Shariat SF, Bolenz C, Karakiewicz PI, Fradet Y, Ashfaq R, Bastian PJ. p53 expression in patients with advanced urothelial cancer of the urinary bladder. BJU Int 2010;105:489-95.
58. Shariat SF, Bolenz C, Godoy G, Fradet Y, Ashfaq R, Karakiewicz PI et al. Predictive value of combined immunohistochemical markers in patients with pT1 urothelial carcinoma at radical cystectomy. J Urol 2009;182:78-84; discussion 84
59. Lamy A, Gobet F, Laurent M, Blanchard F, Varin C, Moulin C et al. Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations. J Urol 2006;176(6 Pt 1):2686-9.
60. Stern MC, Conway K, Li Y, Mistry K, Taylor JA. DNA repair gene polymorphisms and probability of p53 mutation in bladder cancer. Molecular Carcinogenesis 2006;45:715-9.
61. Ryk C, Kumar R, Sanyal S, de Verdier PJ, Hemminki K, Larsson P et al. Influence of polymorphism in DNA repair and defence genes on p53 mutations in bladder tumours. Cancer Lett 2006;241:142-9.
62. López-Knowles E, Hernández S, Kogevinas M, Lloreta J, Amorós A, Tandón A et al. The p53 pathway and outcome among patients with T1G3 bladder tumors. Clin Cancer Res 2006; 12(20 Pt 1):6029-36.
63. Moonen PM, van Balken-Ory B, Kiemeney LA, Schalken JA, Witjes JA. Prognostic value of p53 for high risk superficial bladder cancer with long-term followup. J Urol 2007;177:80-3.
64. Esuvaranathan K, Chiong E, Thamboo TP, Chan YH, Kamaraj R, Mahendran R et al. Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha. Cancer 2007;109:1097-105.
65. Yurakh AO, Ramos D, Calabuig-Fariñas S, López-Guerrero JA, Rubio J, Solsona E et al. Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder. Eur Urol 2006;50:506-15; discussion 515.
66. Harada K, Ogden GR. An overview of the cell cycle arrest protein, p21(WAF1). Oral Oncol 2000;36:3-7.
67. Shariat SF, Chade DC, Karakiewicz PI, Ashfaq R, Isbarn H, Fradet Y et al. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol 2010;183:68-75.
68. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-12.
69. Schrier BP, Vriesema JL, Witjes JA, Kiemeney LA, Schalken JA. The predictive value of p53, p27(kip1), and alpha-catenin for progression in superficial bladder carcinoma. Eur Urol 2006;50:76-82.
70. Richter J, Wagner U, Kononen J, Fijan A, Bruderer J, Schmid U et al. High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol 2000;157:787-94.
71. Del Pizzo JJ, Borkowski A, Jacobs SC, Kyprianou N. Loss of cell cycle regulators p27(Kip1) and cyclin E in transitional cell carcinoma of the bladder correlates with tumor grade and patient survival. Am J Pathol 1999;155:1129-36.
72. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol 1999;17:2941-53.
73. Nagata S. Apoptosis by death factor. Cell 1997;88:355-65.
74. Svatek RS, Herman MP, Lotan Y, Casella R, Hsieh JT, Sagalowsky AI et al. Soluble Fas-A promising novel urinary marker for the detection of recurrent superficial bladder cancer. Cancer 2006;106:1701-7.
75. Yamana K, Bilim V, Hara N, Kasahara T, Itoi T, Maruyama R et al. Prognostic impact of FAS/CD95/APO-1 in urothelial cancers: decreased expression of Fas is associated with disease progression. Br J Cancer 2005;93:544-51.
76. Arai M, Sasaki A, Saito N, Nakazato Y. Immunohistochemical analysis of cleaved caspase-3 detects high level of apoptosis frequently in diffuse large B-cell lymphomas of the central nervous system. Pathology International 2005;55:122-9.
77. Giannopoulou I, Nakopoulou L, Zervas A, Lazaris AC, Stravodimos C, Giannopoulos A et al. Immunohistochemical study of pro-apoptotic factors Bax, Fas and CPP32 in urinary bladder cancer: prognostic implications. Urol Res 2002;30:342-5.
78. Burton PB, Anderson CJ, Corbishly CM. Caspase 3 and p27 as predictors of invasive bladder cancer. N Engl J Med 2000;343:1418-20.
79. Karam JA, Lotan Y, Karakiewicz PI, Ashfaq R, Sagalowsky AI, Roehrborn CG et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol 2007;8:128-36.
80. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 1997;275:1132-6.
81. Ong F, Moonen LM, Gallee MP, ten Bosch C, Zerp SF, Hart AA et al. Prognostic factors in transitional cell cancer of the bladder: an emerging role for Bcl-2 and p53. Radiother Oncol 2001;61:169-75.
82. Kong G, Shin KY, Oh YH, Lee JJ, Park HY, Woo YN et al. Bcl-2 and p53 expressions in invasive bladder cancers. Acta Oncol 1998;37:715-20.
83. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997;3:917-21.
84. Akhtar M, Gallagher L, Rohan S. Survivin: role in diagnosis, prognosis, and treatment of bladder cancer. Adv Anat Pathol 2006;13:122-6.
85. Salz W, Eisenberg D, Plescia J, Garlick DS, Weiss RM, Wu XR et al. A survivin gene signature predicts aggressive tumor behavior. Cancer Res 2005;65:3531-4.
86. Altieri DC. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 2003;22:8581-9.
87. Adida C, Crotty PL, McGrath J, Berrebi D, Diebold J, Altieri DC. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation. Am J Pathol 1998;152:43-9.
88. Smith SD, Wheeler MA, Plescia J, Colberg JW, Weiss RM, Altieri DC. Urine detection of survivin and diagnosis of bladder cancer. JAMA 2001;285:324-8.
89. Schultz IJ, Kiemeney LA, Karthaus HF, Witjes JA, Willems JL, Swinkels DW et al. Survivin mRNA copy number in bladder washings predicts tumor recurrence in patients with superficial urothelial cell carcinomas. Clin Chem 2004;50:1425-8.
90. Shariat SF, Ashfaq R, Karakiewicz PI, Saeedi O, Sagalowsky AI, Lotan Y. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. Cancer 2007;109:1106-13.
91. Shariat SF, Karakiewicz PI, Godoy G, Karam JA, Ashfaq R, Fradet Y et al. Survivin as a prognostic marker for urothelial carcinoma of the bladder: a multicenter external validation study. Clin Cancer Res 2009;15:7012-9.
92. Bochner BH, Cote RJ, Weidner N, Groshen S, Chen SC, Skinner DG et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 1995;87:1603-12.
93. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994;265:1582-4.
94. Grossfeld GD, Ginsberg DA, Stein JP, Bochner BH, Esrig D, Groshen S et al. Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression. J Natl Cancer Inst 1997;89:219-27.
95. Zu X, Tang Z, Li Y, Gao N, Ding J, Qi L. Vascular endothelial growth factor-C expression in bladder transitional cell cancer and its relationship to lymph node metastasis. BJU Int 2006;98:1090-3.
96. Miyata Y, Kanda S, Ohba K, Nomata K, Hayashida Y, Eguchi J et al. Lymphangiogenesis and angiogenesis in bladder cancer: prognostic implications and regulation by vascular endothelial growth factors-A, -C, and -D. Clin Cancer Res 2006;12(3 Pt 1):800-6.
97. Chodak GW, Hospelhorn V, Judge SM, Mayforth R, Koeppen H, Sasse J. Increased levels of fibroblast growth factor-like activity in urine from patients with bladder or kidney cancer. Cancer Res 1988;48:2083-8.
98. Watanabe H, Hori A, Seno M, Kozai Y, Igarashi K, Ichimori Y et al. A sensitive enzyme immunoassay for human basic fibroblast growth factor. Biochem Biophys Res Commun 1991;175:229-35.
99. Shariat SF, Youssef RF, Gupta A, Chade DC, Karakiewicz PI, Isbarn H et al. Association of angiogenesis related markers with bladder cancer outcomes and other molecular markers. J Urol 2010;183:1744-50.
100. Neal DE, Marsh C, Bennett MK, Abel PD, Hall RR, Sainsbury JR et al. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet 1985;1:366-8.
101. Villares GJ, Zigler M, Blehm K, Bogdan C, McConkey D, Colin D et al. Targeting EGFR in bladder cancer. World J Urol 2007;25:573-9.
102. Maclaine NJ, Wood MD, Holder JC, Rees RW, Southgate J. Sensitivity of normal, paramalignant, and malignant human urothelial cells to inhibitors of the epidermal growth factor receptor signaling pathway. Mol Cancer Res 2008;6:53-63.
103. Blehm KN, Spiess PE, Bondaruk JE, Dujka ME, Villares GJ, Zhao YJ et al. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clin Cancer Res 2006;12:4671-7.
104. Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF, Knowles MA. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 2005;24:5218-25.
105. Aveyard JS, Skilleter A, Habuchi T, Knowles MA. Somatic mutation of PTEN in bladder carcinoma. Br J Cancer 1999;80:904-8.
106. Cairns P, Evron E, Okami K, Halachmi N, Esteller M, Herman JG et al. Point mutation and homozygous deletion of PTEN/MMAC1 in primary bladder cancers. Oncogene 1998;16:3215-8.
107. Wang DS, Rieger-Christ K, Latini JM, Moinzadeh A, Stoffel J, Pezza JA et al. Molecular analysis of PTEN and MXIl in primary bladder carcinoma. Int J Cancer 2000;88:620-5.
108. López-Knowles E, Hernández S, Malats N, Kogevinas M, Lloreta J, Carrato A et al. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res 2006;66:7401-4.
109. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006;7:606-19.
110. Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, Stokoe D et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006;9:341-9.
111. Raynaud FI, Eccles S, Clarke PA, Hayes A, Nutley B, Alix S et al. Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 2007;67:5840-50.
112. Knowles MA. Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target. World J Urol 2007;25:581-93.
113. Lindgren D, Liedberg F, Andersson A, Chebil G, Gudjonsson S, Borg A et al. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene 2006;25:2685-96.
114. Dyrskjøt L, Zieger K, Kruhøffer M, Thykjaer T, Jensen JL, Primdahl H et al. A molecular signature in superficial bladder carcinoma predicts clinical outcome. Clin Cancer Res 2005;11:4029-36.
115. Kassouf W, Black PC, Tuziak T, Bondaruk J, Lee S, Brown GA, Adam L et al. Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J Urol 2008;179:353-8.
116. Jimenez RE, Hussain M, Bianco FJ Jr, Vaishampayan U, Tabazcka P, Sakr WA et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 2001;7:2440-7.
117. Mellon JK, Lunec J, Wright C, Horne CH, Kelly P, Neal DE. C-erbB-2 in bladder cancer: molecular biology, correlation with epidermal growth factor receptors and prognostic value. J Urol 1996;155:321-6.
118. Chow NH, Chan SH, Tzai TS, Ho CL, Liu HS. Expression profiles of ErbB family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin Cancer Res 2001;7:1957-62.
119. Liedberg F, Anderson H, Chebil G, Gudjonsson S, Höglund M, Lindgren D et al. Tissue microarray based analysis of prognostic markers in invasive bladder cancer: much effort to no avail? Urol Oncol 2008;26:17-24.
120. Gandour-Edwards R, Lara PN Jr, Folkins AK, LaSalle JM, Beckett L, Li Y et al. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer 2002;95:1009-15.
121. Krüger S, Weitsch G, Büttner H, Matthiensen A, Böhmer T, Marquardt T et al. HER2 overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic implications. Int J Cancer 2002;102:514-8.
122. Sato K, Moriyama M, Mori S, Saito M, Watanuki T, Terada K et al. An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer 1992;70:2493-8.
123. Kolla SB, Seth A, Singh MK, Gupta NP, Hemal AK, Dogra PN et al. Prognostic significance of Her2/neu overexpression in patients with muscle invasive urinary bladder cancer treated with radical cystectomy. Int Urol Nephrol 2008;40:321-7.
124. Bolenz C, Shariat SF, Karakiewicz PI, Ashfaq R, Ho R, Sagalowsky AI et al. Human epidermal growth factor receptor 2 expression status provides independent prognostic information in patients with urothelial carcinoma of the urinary bladder. BJU Int 2010 [Epub ahead of print].
125. Boorjian S, Ugras S, Mongan NP, Gudas LJ, You X, Tickoo SK et al. Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. Urology 2004;64:383-8.
126. Tuygun C, Kankaya D, Imamoglu A, Sertcelik A, Zengin K, Oktay M et al. Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: A comparative analysis of clinicopathological features and survival outcomes according to receptor expression. Urol Oncol 2009 [Epub ahead of print].
127. Bolenz C, Lotan Y, Ashfaq R, Shariat SF. Estrogen and progesterone hormonal receptor expression in urothelial carcinoma of the bladder. Eur Urol 2009 [Epub ahead of print].
128. Shen SS, Smith CL, Hsieh JT, Yu J, Kim IY, Jian W et al. Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue. Cancer 2006;106:2610-6.
129. Basakci A, Kirkali Z, Tuzel E, Yorukoglu K, Mungan MU, Sade M. Prognostic significance of estrogen receptor expression in superficial transitional cell carcinoma of the urinary bladder. Eur Urol 2002;41:342-5.
130. Cordon-Cardo C, Zhang ZF, Dalbagni G, Drobnjak M, Charytonowicz E, Hu SX et al. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 1997;57:1217-21.
131. Blaveri E, Simko JP, Korkola JE, Brewer JL, Baehner F, Mehta K et al. Bladder cancer outcome and subtype classification by gene expression. Clin Cancer Res 2005;11:4044-55.
132. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 2006;24:778-89.
133. Lindgren D, Frigyesi A, Gudjonsson S, Sjödahl G, Hallden C, Chebil G et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res 2010;70:3463-72
134. Takata R, Katagiri T, Kanehira M, Tsunoda T, Shuin T, Miki T et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res 2005;11:2625-36.